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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
Primary objective
To assess the efficacy of AT for memory support in people with dementia in terms of daily performance of Activities of Daily Living
(ADL) and dependency. Furthermore, the effects on perceived quality of life of people with dementia will be explored.
Secondary objective
To identify the variety, quality, and feasibility of the available interventions for people with dementia, and thereby gain insight into the
applicability of AT to support people with dementia with their memory problems. The impact on informal carer burden, self esteem,
mood and feeling of competence and the formal carers’ work satisfaction, work load, and feelings of competence will be studied as well.
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B A C K G R O U N D
Daily life without Information Communication Technology
(ICT) is almost unthinkable tomany people nowadays. ICT serves
many purposes including safety, navigation, or social contact and
is applied in many environments, including health and social care
settings. New developments in health care to support people in
improving their well-being by means of ICT are encouraged by
governments (Kamel Boulous 2009). Also, the European Com-
mission stimulates the development of Assistive Technology to
prevent people with disabilities being excluded from society by
funding programmes like e-Inclusion and Ambient Assisted Liv-
ing (AAL) (European Commission 2010). Consequently, in the
last two decades ICT has increasingly been developed to support
people with cognitive impairment, for example related to demen-
tia, in their daily lives.
ICT-based devices developed for people with dementia are usu-
ally referred to as Assistive Technology (AT), but other terminol-
ogy is also used, including telecare, cognitive prosthetics, tech-
nology-based reminding support, and pervasive computing. AT
has been developed to support people with dementia and their
carers to manage their daily activities and to enhance safety. Sev-
eral reports describe designing AT for groups with cognitive im-
pairment (Cahill 2007; Hanson 2007; Meiland 2007; Mulvenna
2010; Nugent 2008; Rialle 2008; Sixsmith 2007; Sterns 2005;
Van der Roest 2008). Some successful AT devices like electronic
pill boxes, picture phones, or mobile tracking devices are already
commercially available but, due to the lack of well-designed trials
and small sample sizes in trials, their usefulness and effectiveness
for people with dementia are not always clear. Furthermore, a wide
range of devices and a diversity of people with cognitive impair-
ments are involved in the different studies, whichmakes it difficult
to draw firm conclusions on the usefulness and effectiveness of AT
for this target group (Lauriks 2007; Topo 2009).
In their review, Lauriks 2007 described that AT is intended to sup-
port people with dementia in the four areas of general and person-
alised information; practical support with regard to symptoms of
dementia; social contact and company; and healthmonitoring and
perceived safety. This review will focus on memory problems, one
of the most common symptoms in people with dementia. These
problems have a high impact on functioning in daily life. Many
people with dementia, as well as their informal carers, report a lack
of adequate support for memory problems (Van der Roest 2009).
In addition to the more traditional means of memory support,
for example diaries, written signs, journals or notes, ICT applica-
tions could offer effective alternatives. It is expected that electronic
memory support devices will enable people with dementia to live
more independently and will alleviate carer burden (Cahill 2007).
Description of the condition
The dementia syndrome is usually caused by a chronic or progres-
sive disease of the brain. The most common forms of dementia
are Alzheimer’s Disease and vascular dementia. Dementia causes
impairment in higher cortical functioning, including memory,
thinking, orientation, comprehension, and judgement. The cog-
nitive impairment in dementia is often preceded by the deteriora-
tion of emotional control, social behaviour, or motivation (WHO
2007). Performing tasks of daily living becomes increasingly dif-
ficult. Initially the more complex instrumental activities of daily
living (IADL) are affected and then later on personal ADL tasks
are affected (Liu 2007; Öhman 2001; Sikkes 2009; VanWielingen
2004). Functional decline is one of the core diagnostic criteria
as it is common in all types of dementia (American Psychiatric
Association 1994). As the disease progresses people experience
more and more functional problems in daily living, eventually be-
coming totally dependent on the help of others (Agüero-Torres
1998; Wimo 1999). Many people in the most advanced stages of
dementia are admitted to a long-term care facility to receive full
time care. It is estimated that in high income countries approxi-
mately 34% of the people with dementia live in long-term care fa-
cilities (Alzheimer’s Disease International 2010). Worldwide, ap-
proximately 5% of all people over 65 years have dementia and
with the population ageing this number is estimated to double
every 20 years, to reach 115 million by 2050 (Alzheimer’s Disease
International 2009).
Due to their condition, people with dementia increasingly rely on
the support of others. This help is frequently provided by informal
carers, family, or relatives who provide unpaid care. If informal
care is no longer sufficient, feasible, or not available, paid staff
step in to provide support (as formal carers). The estimated global
costs for dementia are currently estimated to be USD 604 billion,
of which the majority is attributed to informal care (42%) and
social care (care provided by community care professionals and in
long-term care settings) (42%). The direct medical costs are much
lower (16%) (Alzheimer’s Disease International 2010). With an
estimated increase in costs of 85% by the year 2030, Alzheimer’s
Disease International stresses the urgent need to develop cost-ef-
fective packages of medical and social care for people with demen-
tia.
Description of the intervention
People with dementia experience prospective or retrospective
memory problems, or both. The type of memory impairment ex-
perienced is dictated by the underlying condition, the resultant
site, and the extent of the brain lesion. Prospective memory (PM)
is essential for living independently as it involves remembering to
do things in the future without any prompting; whilst retrospec-
tive memory (RM) involves recalling or recognizing information
that one has acquired in the past (Maylor 2002). Recent research
showed that people with mild dementia would appreciate devices
that could support their PM and RM; remind them of events at
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prescheduled points in time such as taking medication, eating, or
keeping appointments; and could help them to locate lost items,
remember names of people, the day and time (Nugent 2007).
Depending on the function that an electronic device is developed
for, the devices have specific requirements. Some ATs can be cus-
tomised on, or react to, the environment or its’ user in a dynamic
way, for example locomotion sensors that only activate a warning,
alarm, or camera if no movement is detected for a defined pe-
riod of time. Other devices are used as stand-alone, like electronic
calenders; whilst some are integrated into a more comprehensive
system placed in the living environment of its’ user, like the COG-
KNOW device (Meiland 2007). Devices can also be mobile, for
example tracking systems, enabling the user to take the device with
them outside their home. AT devices that aim to support general
prospective memory functioning need to be more advanced and
might gain less effects than AT devices for retrospective memory
problems, since the retrospective memory is in general less dis-
turbed than the prospective memory in dementia.
How the intervention might work
People withmemory problems often rely on others around themor
on static reminders or cues like written notes or diaries to support
their memory. By providing an AT that reminds them of mean-
ingful events, previous daytime activities, or guides them through
complex situations or tasks, people with dementia may act more
independently. They will attain their daily goals (for example ap-
pointments, activities), may be less agitated or confused, and will
experience a better quality of life; and their informal carers may
experience less burden (Cahill 2007). Naturally the assistive tech-
nology should be adapted and fine-tuned to dementia-related and
other personal and context-related factors (Dröes 2010). Levels
of technology used for AT devices vary from low technology to
personalised technology and context aware (smart) environments.
Electronic calendars are examples of low technology devices, not
taking into account whether or not the person with dementia fol-
lows the given reminder. More context aware devices do exist, like
mobile tracking devices that automatically give a warning when a
person with dementia is leaving his or her familiar area. Although
technology for context aware environments does exist, it is not yet
part of mainstream provision due to its current sensitivity to errors
and false alarms.
Why it is important to do this review
Many assistive devices have been developed formemory support in
people with cognitive impairment, such as dementia.However, the
usefulness, user-friendliness, and intended effects of these devices,
especially for people with dementia, are not always evident or
studied. Although reviews of (electronic) memory aids do exist
(Bharucha 2009; Caprani 2006; Fritschy 2004; Lauriks 2007;
Lindenberger 2008; Topo 2009), a systematic review of studies
focusing on the efficacy of AT for memory support in people with
dementia is lacking. It is important to review to what extent the
efficacy, usefulness, and user-friendliness of these devices has been
proven, and to assess the quality of such studies. This will help to
gain insight into the existing evidence-based supportive devices.
A comprehensive overview of evidence-based devices will guide
people with dementia and their informal and professional carers
in selecting a prospective memory device that meets the needs of
its’ user. The review will also provide useful information for AT
developers in this rapidly growing area, by addressing the gaps
in, and possible shortcomings of, the state-of-the-art in AT for
memory support.
O B J E C T I V E S
Primary objective
To assess the efficacy of AT for memory support in people with
dementia in terms of daily performance of Activities of Daily Liv-
ing (ADL) and dependency. Furthermore, the effects on perceived
quality of life of people with dementia will be explored.
Secondary objective
To identify the variety, quality, and feasibility of the available in-
terventions for people with dementia, and thereby gain insight
into the applicability of AT to support people with dementia with
their memory problems. The impact on informal carer burden,
self esteem, mood and feeling of competence and the formal car-
ers’ work satisfaction, work load, and feelings of competence will
be studied as well.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and cluster randomised tri-
als with blinded assessment of outcome will be included in the
review (including those with inadequate sequence allocation). As
the development of AT is a relatively new area, we do not expect
to find many RCTs on this topic.
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Types of participants
Participants need to be diagnosed with dementia according to
the Diagnostic and Statistical Manual IV (American Psychiatric
Association 1994) or ICD-10 (WHO 2007). If diagnostic infor-
mation on participants is not described in potential studies, pri-
mary authors will be asked for additional diagnostic information.
If the provided information is according to the criteria set, these
studies will be included. No further inclusion criteria for partici-
pants shall be applied.
Types of interventions
The interventions that will be included in the review evaluate an
assistive device, driven by electronics with the single aim of sup-
portingmemory problems. The electronic device under evaluation
could be stand alone or integrated in a service system (remotely
configurable), stationary or mobile. The devices under study will
most likely require configuration or help with setting-up by car-
ers. The focus will primarily be on the person with dementia, but
the impact on carers will be reviewed as well. Interventions that
evaluate a combination of devices that are provided with different
aims will not be included. The control interventions may either
be ’care as usual’ or non-technological psychosocial interventions
(including interventions that use non-electronic assistive devices)
aimed at supporting memory problems.
Types of outcome measures
The primary outcome measures regarding the efficacy of the AT
under study will relate to ADL and the level of dependency of peo-
ple with dementia. The secondary outcome measures will relate
to clinical and care-related outcomes of the AT for people with
dementia, to their perceived quality of life and well-being, and also
on the effects of AT on their carers, informal carers for commu-
nity-based interventions and formal carers for institutional-based
interventions. Adverse events of AT for people with dementia and
(in)formal carers will also be reported. The validity and reliability
of the outcome measures used will be reported. All reported time
frames will be included. All outcomes measured will be listed.
Primary outcomes
Daily functioning
• Activities of daily living (ADL): personal (PADL) and
instrumental (IADL)
• Level of dependency (self report or proxy report)
• Admission to long-term care (for community-based
interventions)
Secondary outcomes
User reports
• Experienced autonomy (self report)
• Experienced usefulness and user-friendliness of AT (self
report)
• Adoption of AT
Clinical
• Cognitive functioning
• Neuropsychiatric symptoms (behavioural and mood
problems)
Care
• Need for informal care
• Need for formal care
Well-being
• Perceived quality of life or well-being (self report or proxy
report)
Informal carer
• Carer burden
• Self esteem
• Feelings of competence
Formal carer
• Work satisfaction
• Workload
• Feelings of competence
Adverse events
• Clinical
• Care
• Informal carer
• Formal carer
Search methods for identification of studies
Relevant studies will be identified by searching various databases
from January 1990 to date.
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Electronic searches
We will search ALOIS (www.medicine.www.medicine.ox.ac.uk/
aloisox.ac.uk/alois), the Cochrane Dementia and Cognitive Im-
provement Group Specialized Register. The search terms used will
be: technology, device, ICT, assistive, orthotic.
ALOIS is maintained by the Trials Search Co-ordinator of the
CochraneDementia and Cognitive ImprovementGroup and con-
tains dementia studies identified from the following.
1. Monthly searches of a number of major healthcare
databases: MEDLINE, EMBASE, CINAHL, PsycINFO and
LILACS.
2. Monthly searches of a number of trial registers: meta
Register of Controlled Trials; Umin Japan Trial Register; WHO
portal (which covers ClinicalTrials.gov; ISRCTN; Chinese
Clinical trials Register; German Clinical trials register; Iranian
Registry of Clinical trials, and the Netherlands National Trials
Register, plus others).
3. Quarterly search of the Cochrane Central Register of
Controlled Trials (CENTRAL) (The Cochrane Library).
4. Monthly searches of a number of grey literature sources: ISI
Web of Knowledge Conference Proceedings; Index to Theses;
Australian Digital Theses.
To view a list of all sources searched for ALOIS, see About ALOIS
on the ALOIS website.
Additional separate searches will be run in many of the above
sources to ensure that the most up-to-date results are retrieved.
The search strategy that will be used for the retrieval of reports of
trials from MEDLINE (via the Ovid SP platform) can be seen in
Appendix 1.
Further searches will be carried out in the following specialist
sources.
• PiCarta (until date).
• OT seeker (until date).
• ADEAR (until date).
• Ageline (until date).
• AgeInfo (until date).
• Social Care Online (until date).
• Centre for Reviews and Dissemination (CRD) Databases
(until date).
• The Collection of Computer Science Bibliographies (until
date).
• DBLP Computer Science Bibliography (until date).
• Networked Computer Science Technical Reference Library
(NCSTRL) (until date).
• Computing Research Repository (CoRR) (until date).
• IEEE Computer Society Digital Library (until date).
• Springer Link Lecture Notes (until date).
• HCI Bibliography: Human-Computer Interaction
Resources (until date).
• Inspec (until date).
• J-STAGE: Japan Science and Technology Information
Aggregator, Electronic (until date).
For each database the search will be adapted. There will be no
language restriction.
Searching other resources
Additionally, Google Scholar and OpenSIGLE will be searched
for grey literature. References of identified articles will be hand-
searched using the snowball method in order to find other poten-
tially relevant studies.
Data collection and analysis
The first review author (HvdR) will execute the search strategy as
described, supported by the second review author (JW).
Selection of studies
The search results will be merged using reference management
software and duplicate records removed. Study titles and abstracts
will be screened for appropriateness by HvdR and JW working
independently. Obviously irrelevant reports will be removed.Mul-
tiple reports of the same study will be linked.
Full text versions of potentially relevant reports will be obtained
and examined independently by HvdR and JW to assess compli-
ance with the predefined eligibility criteria. When suitability of a
study is unclear, after examining the full text the corresponding
author will be contacted to request clarification or additional in-
formation, or both. Both authors will compare and discuss their
selection of titles until agreement is reached. If uncertainty on in-
clusion remains after discussion, the third and fourth review au-
thors (RMD andMO)will be consulted. Studies excluded because
of poor quality will be identified in the ’Characteristics of excluded
studies’ table together with the reasons for exclusion.
Data extraction and management
Data from the selected studies will be independently extracted by
HvdR and JW, using a predesigned data collection form that will
be pilot tested prior to its use. Data from multiple reports of the
same study will be collated onto one form. Study names will not
be masked. Agreement on data extraction will be sought by means
of discussion between HvdR and JW. If there is disagreement, the
third and fourth review authors (RMD and MO) will be con-
sulted. Study authors will be contacted for any missing data. Data
categories will include the following.
• Method: study design; study dates and duration; sequence
generation; allocation sequence concealment; blinding of
participants, personnel and outcome assessors.
• Participants: total number of participants, reasons why
excluded, type of setting, number of locations, diagnostic
criteria, age, gender, and country.
• Interventions: total number of interventions and
comparators, and description of the content for each
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intervention; type of technology used, categorised by function of
device under study according to relevant ISO 9999:2007
classifications (British Standard 2007); integrity and fidelity
measures such as adherence, quality of delivery, and participant’s
responsiveness.
• Outcomes: total number of outcome measures, and time
points collected and reported. For each outcome measured:
definition, procedure, upper and lower limits of scales and
direction, validity and reliability of instruments used.
• Results: number of participants allocated and analysed in
each group and for each outcome of interest; sample size,
participants lost to follow-up; summary data and estimate of
effect with confidence level and P value for for each intervention
group; subgroup analyses.
• Miscellaneous: funding source, ethical approval, consent
procedures, key conclusions.
Dichotomous measures: the numbers in each of the two outcome
categories within each of the intervention groups.
Continuous measures: the mean value, standard deviation (SD)
and number of participants (N) for each outcome measurement
in each intervention group at each time point.
Ordinal measures: as RevMan does not enable themeta-analysis of
ordinal measures, shorter scales will be converted to dichotomous
data by combining adjacent categories, based on clinical relevance;
and longer scales will be treated as continuous data, and the po-
tential resulting bias noted.
Assessment of risk of bias in included studies
The selected studies will be critically evaluated by HvdR and JW
working independently. For RCTs the criteria as derived from the
Cochrane Collaboration’s tool for assessing risk of bias will be used
(Higgins 2008a), namely risk of bias due to: selection, perfor-
mance, attrition, detection, and reporting. In a meta-analysis, risk
of bias within cluster RCTs include: issues of recruitment, baseline
imbalance, sample size, number or loss of clusters, incorrect anal-
ysis, and inclusion of both cluster and individually randomised
trials or trials with different types of clusters.
Measures of treatment effect
A single summary statistic will be calculated to represent the effect
found in each study as follows.
Dichotomous (binary) measures: odds ratio (OR) and risk differ-
ence (RD) with 95% confidence intervals (CI).
Continuous measures: mean difference (MD) between baseline
and post-intervention endpoint, and change, weighted mean dif-
ference (WMD) for data using the same scales and standardized
mean difference (SMD) for data using different scales.
Studies will be weighted according to size and degree of variability.
Unit of analysis issues
The analysis will take into account the level at which randomisa-
tion occurred with each study. Studies with non-standard designs
will not be excluded, and appropriate analysis methods will be
used (Higgins 2008b). If an incorrect analysis method is reported
then an approximate analysis will be attempted, along with the
necessary sensitivity analysis of any assumptions made.
Dealing with missing data
Wherever possible, the original investigators will be contacted to
request missing data. If standard deviations (SDs) are not reported
and further information is not obtained from the investigators,
they will be calculated via the standard error of the mean (SEM).
The amount and type of missing data related to participants lost to
a study that can not be obtained from the original investigators will
be described in the ’Characteristics of included studies’ table and
the potential impact discussed, which will depend on the extent of
missing data. Intention-to-treat (ITT) analysis will be conducted
by imputing outcomes for the missing participants using the last
observation carried forward approach.
Assessment of heterogeneity
Variability between the included studieswill be reported as follows.
• Clinical: participants, interventions, technology, and
outcomes.
• Methodological: study design and risk of bias.
• Statistical: if the observed intervention effects are more
different from each other than would be expected due to chance
alone.
• Technology: type of technology.
Substantial statistical heterogeneity will be suggested by the fol-
lowing indicators: poor overlap of confidence intervals on forest
plots; high Chi2 values, P > 0.10, and I2 statistic > 50%.
Assessment of reporting biases
Reporting biases will be detected using funnel plots, to assess if the
association between estimated intervention effects and a measure
of study size (such as the SEM or log OR) is greater than might be
expected to occur by chance. Funnel plot asymmetry (indicating
small study effects) will initially be tested by visual inspection. If
more than 10 studies are found to be eligible, funnel plots will
be tested by linear regression of the intervention effect estimates
on their SEMs, weighted by 1 (variance of the intervention effect
estimate) for continuous measures; and linear regression of the log
ORs on its SEM, weighted by the inverse of the variance of the log
OR for dichotomous measures (Egger 1997). If small scale study
effects are found, sensitivity analysis will be conducted to compare
the fixed-effect model and random-effects model estimates of the
intervention effects.
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Data synthesis
Results of all studies will be pooled in the first instance regard-
less of the type of AT used in the intervention, but based on out-
come measures. This is because we do not expect to find many
studies that evaluate similar devices. If allowed by the data, re-
sults will be pooled by type of assistive device used and diagnos-
tic subgroups (different types of dementia). In the first instance,
fixed-effect models will be used. If heterogeneity is detected then
random-effects models will be used (Deeks 2008). If the data can
not be pooled for reasons of incomparability, study results will be
summarized and reported separately.
Reports on usefulness and user-friendliness will not generate
change scores since these measures will only be administered in
experimental groups. Meta-analyses on these results will not be
performed, but summary statistics (N, mean values and standard
deviations) shall be reported.
Subgroup analysis and investigation of heterogeneity
Clinical variables whichmightmodify the efficacy of assistive tech-
nology interventions and which might form the basis of subgroup
analyses, should sufficient data be available, are:
• people with different types of dementia;
• level of dementia;
• age;
• gender;
• institutional versus community setting;
• living together with carer versus living alone;
• technology type (stand-alone, integrated, mobile);
• level of technology (ranging from low technology to context
aware).
Sensitivity analysis
Decisions taken throughout the systematic review process includ-
ing, but not limited to: which studies were included, cut-off points
for age, or outcome measure values used will be recorded and re-
viewed on completion. A sensitivity analysis will be performed to
address the following questions.
• Are the findings influenced by the choice of statistical
model?
• Is there bias in the study methods?
• Are the findings robust to different assumptions (missing
data, ITT analysis)?
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
Source Search strategy
MEDLINE (via Ovid SP) 1. exp Dementia/
2. Delirium/
3. Wernicke Encephalopathy/
4. Delirium, Dementia, Amnestic, Cognitive Disorders/
5. dement*.mp.
6. alzheimer*.mp.
7. (lewy* adj2 bod*).mp.
8. deliri*.mp.
9. (chronic adj2 cerebrovascular).mp.
10. (“organic brain disease” or “organic brain syndrome”).mp
11. (“normal pressure hydrocephalus” and “shunt*”).mp.
12. “benign senescent forgetfulness”.mp.
13. (cerebr* adj2 deteriorat*).mp.
14. (cerebral* adj2 insufficient*).mp.
15. (pick* adj2 disease).mp.
16. (creutzfeldt or jcd or cjd).mp.
17. huntington*.mp.
18. binswanger*.mp.
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(Continued)
19. korsako*.mp.
20. or/1-19
21. “cognit* impair*”.mp.
22. exp *Cognition Disorders/
23. MCI.ti,ab.
24. ACMI.ti,ab.
25. ARCD.ti,ab.
26. SMC.ti,ab.
27. CIND.ti,ab.
28. BSF.ti,ab.
29. AAMI.ti,ab.
30. MD.ti,ab.
31. LCD.ti,ab.
32. QD.ti,ab.
33. AACD.ti,ab.
34. MNCD.ti,ab.
35. MCD.ti,ab.
36. (“N-MCI” or “A-MCI” or “M-MCI”).ti,ab.
37. ((cognit* or memory or cerebr* or mental*) adj3 (declin* or impair* or los* or deteriorat* or
degenerat* or complain* or disturb* or disorder*)).ti,ab
38. “preclinical AD”.mp.
39. “pre-clinical AD”.mp.
40. (“preclinical alzheimer*” or “pre-clinical alzheimer*”).mp
41. (aMCI or MCIa).ti,ab.
42. (“CDR 0.5” or “clinical dementia rating scale 0.5”).ti,ab
43. (“GDS 3” or “stage 3 GDS”).ti,ab.
44. (“global deterioration scale” and “stage 3”).mp.
45. “Benign senescent forgetfulness”.ti,ab.
46. “mild neurocognit* disorder*”.ti,ab.
47. (prodrom* adj2 dement*).ti,ab.
48. (episodic* adj2 memory).mp.
49. (“preclinical dementia” or “pre-clinical dementia”).mp.
50. or/21-49
51. 20 or 50
52. technology.ti,ab.
53. (“information communications technology” or ICT).ti,ab.
54. Technology/
55. exp Self-Help Devices/
56. orthot*.ti,ab.
57. prosthetic*.ti,ab.
58. device*.ti,ab.
59. telecare.ti,ab.
60. electronic.ti,ab.
61. digit*.ti,ab.
62. “pervasive computing”.mp
63. or/52-62
64. 51 and 63
65. randomized controlled trial.pt.
10Assistive technology for memory support in dementia (Protocol)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
66. controlled clinical trial.pt.
67. randomized.ab.
68. placebo.ab.
69. drug therapy.fs.
70. randomly.ab.
71. trial.ab.
72. groups.ab.
73. or/65-72
74. (animals not (humans and animals)).sh.
75. 73 not 74
76. 64 and 75
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